Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain
The president of a wholesale dealer who “unknowingly” introduced fake Harvoni (ledipasvir + sofosbuvir) into the Japanese drug supply chain finally met the press on March 23, apologizing for the fiasco and revealing how he purchased what was later found…
To read the full story
Related Article
- Tokyo Govt Orders 2 “Cash-and-Carry” Dealers to Suspend Business
April 14, 2017
- 2 Kansai Medico Pharmacy Outlets Ordered to Suspend Biz
March 17, 2017
- Tokyo, Osaka Govts Issue Biz Improvement Order to Dealers over Fake Harvoni
March 14, 2017
- 3 Kansai Medico Pharmacies Slapped with Biz Improvement Order over Fake Harvoni
March 7, 2017
- MHLW Mulls Administrative Penalties, Tighter Regulations after Counterfeit Harvoni Case
February 14, 2017
- MHLW Wraps Up Probe into Fake Harvoni after Distribution Routes “Most Likely” Identified
February 2, 2017
- MHLW Pins Down Distribution Routes for Harvoni Counterfeits; Composition of Fake Pills Identified
February 1, 2017
- Kansai Medico Used Non-Official Harvoni Dealer for Cheaper Price
January 25, 2017
- Counterfeit Harvoni Found in Tokyo Too, Route Identified for a Nara Bottle
January 24, 2017
- Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution
January 18, 2017
BUSINESS
- TS Alfresa-Backed Drone Council Inks Pact with Hiroshima
October 19, 2026
- Santen to Seek Bankruptcy for Chinese Subsidiary
October 19, 2026
- Toho Invests in Keio Offshoot AdipoSeeds
October 19, 2026
- Amgen, JASSO Team Up on Obesity Research and Care
October 19, 2026
- Sanwa Kagaku to Resume Kumamoto Production on October 19
October 19, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…